Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, told DirectorsTalk today the appointment of U.S. healthcare investment bank MTS Health Partners (MTS) to advise on its future financing options within the U.S. market. A NASDAQ listing continues to be an option for Motif in order to be aligned with several peer companies.
The Company has appointed as its auditor PricewaterhouseCoopers LLP (PwC), one of the top four multinational professional services firms in the world.
Considerable progress has also been made with plans to identify strategic partners who are interested in licensing our Phase III asset, iclaprim, outside the U.S.
Graham Lumsden, CEO of Motif, said: “For Motif to continue to grow and become a leading antibiotic company, and in order to continue to build value for our existing shareholders, it is important that we explore the capital markets in the U.S., including the potential for a NASDAQ listing. With the appointment of MTS, we can make the right decisions on how to proceed during 2016.
“The accomplishments in 2015 – listing on AIM in April, raising £25 million including the follow-on in July, being granted QIDP designation for iclaprim by the FDA, and completing the manufacture of clinical trial supplies, have strengthened the Company and positioned us for continued success in 2016.”
